SCHEMBL2865098

SCHEMBL2865098

COc1ccc(Cl)c(-n2cc3c(=O)[nH]c4cc(NCCCN5CCOCC5)ccc4c3n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.49
TLR9 Q9NR96 2/20 0.43
TLR7 Q9NYK1 2/20 0.43
RAD52 P43351 2/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 3/20 0.41
LMNA P02545 2/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 1/20 0.41
IDE P14735 1/20 0.41
HPGD P15428 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
SIGMAR1 Q99720 1/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
USP2 O75604 1/20 0.40
MCL1 Q07820 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2864783 0.90 KDM4E (0.53) KDM4ENPC1MAPTHTTALDH1A1
SCHEMBL2867332 0.89 NPC1 (0.43) KDM4ERAD52NPC1RAB9AL3MBTL1
SCHEMBL2870092 0.88 KDM4E (0.53) KDM4ENPC1MAPTALDH1A1MEN1
SCHEMBL2859143 0.84 KDM4E (0.45) KDM4ETLR9TLR7RAD52NPC1
SCHEMBL13025281 0.78 KDM4E (0.55) KDM4EMAPTALDH1A1HPGDMEN1
Hydrochloric Acid SCHEMBL2868690 0.77 KDM4E (0.54) KDM4EMAPTALDH1A1HPGDMEN1
SCHEMBL2868414 0.76 ADORA3 (0.51) KDM4ENPC1LMNAALDH1A1HPGD
SCHEMBL2867992 0.76 ADORA3 (0.51) KDM4ENPC1LMNAHTTALDH1A1
SCHEMBL2861165 0.74 KDM4E (0.49) KDM4ENPC1MAPTALDH1A1MEN1
SCHEMBL2868762 0.74 NPC1 (0.40) KDM4ERAD52NPC1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed
EP-1719771-A1 PYRAZOLOQUINOLONE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 KDM4E 1057/4885TLR9 3581/4885TLR7 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.